🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Beclomethasone dipropionate 100 µg + formoterol fumarate 6 µg

Found 40 matching trials

Efficacy and Tolerability of Beclomethasone Dipropionate/Formoterol Single Inhaler in Patients With Mild to Moderate Persistent Asthma

PHASE3

Efficacy and tolerability of the fixed combination Beclomethasone Dipropion...

Status

Completed

Location

Multiple Locations

Start Date

2004-08

Trial ID

NCT00862264

Treatments Being Tested

Fixed combination Beclomethasone Dipropionate/Formoterol HFA 134a-pMDI

Study in Adult Patients With Moderate to Severe Asthma

PHASE3

This study assessed the influence of pink vs. white pressurized metered-dos...

Status

Completed

Location

Chiesi Clinical Trial Site 38011

Start Date

2022-02-24

Trial ID

NCT04886999

Treatments Being Tested

Beclomethasone dipropionate 100 µg / Formoterol fumarate 6 µg (Inhaler A)Beclomethasone dipropionate 100 µg / Formoterol fumarate 6 µg (Inhaler B)

A Study in Patients With Asthma

PHASE3

The purpose of the present study is to demonstrate the higher efficacy of F...

Status

Completed

Location

Dipartimento Cardio-Polmonare - Azienda Ospedaliero-Universitaria - Padiglione Rasori

Start Date

2012-07

Trial ID

NCT01570478

Treatments Being Tested

Foster® NEXThaler® 100/6 µg/unit dose Seretide® Accuhaler® 250/50 µg/actuation

Bronchodilator Effect of CHF1535 pMDI Versus Free Combination of Beclometasone Plus Formoterol pMDI in Asthmatic Children

PHASE2

The purpose of this clinical study is to compare the improvement in breathi...

Status

Completed

Location

Poradnia Alergologiczna

Start Date

2011-12

Trial ID

NCT01584492

Treatments Being Tested

beclomethasone+formoterol 50/6 (1 inhalation)CHF 1535 50/6 (2 inhalations)CHF 1535 50/6 (4 inhalations)Formoterol + Beclomethasone dipropionate Placebo (6 inhalations)

CHF5993 and CHF1535 pMDI on Lung Hyperinflation and Exercise Endurance Time in Subjects With COPD

PHASE4

Double Blind, Multinational, Multicentre, Randomised, Placebo-Controlled, 3...

Status

Completed

Location

PAREXEL International GmbH Early Phase Clinical Unit Berlin

Start Date

2021-10-28

Trial ID

NCT05097014

Treatments Being Tested

CHF5993 CHF1535 Matched placebo

Efficacy and Tolerability of Beclometasone/Formoterol Single Inhaler in Patients With Moderate to Severe Persistent Asthma

PHASE3

Efficacy and tolerability of the fixed combination beclometasone/formoterol...

Status

Completed

Location

Multiple Locations

Start Date

2004-02

Trial ID

NCT00476268

Treatments Being Tested

beclomethasone/formoterol (100/6µg) pMDI Beclometasone dipropionate 250 µg/unit dose pMDI Formoterol powder 12 µg/unit dose

TRIple in asthMA With uncontRolled pAtient on Medium streNgth of ICS + LABA

PHASE3

Evaluate the superiority of CHF 5993 100/6/12.5 µg Pressurised Metered Dose...

Status

Completed

Location

Chiesi Clinical Trial Site 276814

Start Date

2016-02-17

Trial ID

NCT02676076

Treatments Being Tested

CHF 5993 100/6/12.5 CHF 1535 100/6 µg

A Study to Evaluate the Onset of Relief From Methacholine-induced Bronchoconstriction With CHF1535 NEXThaler in Asthmatic Patients.

PHASE2

The clinical trial is designed to evaluate the non-inferiority of CHF1535 1...

Status

Completed

Location

University of Dundee

Start Date

2017-02-28

Trial ID

NCT03108534

Treatments Being Tested

CHF1535 NEXThaler CHF1535 pMDI Placebo

Clinical Study to Evaluate the Safety, Tolerability and the Concentration of the BDP (Beclomethasone Dipropionate), Active Metabolite of BDP, FF( Formoterol Fumarate) and GB (Glycopyrronium Bromide), After Inhalation of CHF 5993 at Two Different Doses and QVAR®

PHASE1

The study is being conducted to compare the pharmacokinetic (PK) of BDP (an...

Status

Completed

Location

SGS Belgium NV - Clinical Pharmacology Unit

Start Date

2023-04-24

Trial ID

NCT05898984

Treatments Being Tested

Test product (T):CHF 5993 BDP/FF/GB 200/6/12.5 µg pMDI Reference product 1 (R1): CHF 5993 BDP/FF/GB 100/6/12.5 µg pMDI Reference product 2 (R2): BDP HFA (QVAR REDIHALER®, BDP 80 μg)

Triple in Asthma Dose Finding

PHASE2

Primary objective The primary objective was to evaluate the efficacy of a ...

Status

Completed

Location

Chiesi Clinical Trial Site 0105

Start Date

2014-04-11

Trial ID

NCT02127866

Treatments Being Tested

CHF 5259 plus Foster 100/6 µg Foster 100/6 µg (four puffs BID)

Previous Next